| Intrinsic Valuation of: SYNGENE | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 9 | Market Cap | ₹182B | |||||
| 2021 | - | - (-) | P/E Ratio | 52 | Total Asset | ₹68B | |||||
| 2022 | ₹1B | - (-) | Net Income | ₹5B | Total Debt | ₹0 | |||||
| 2023 | ₹3B | 190.4% (136.3%) | EBITDA | ₹11B | Total Liab | ₹21B | |||||
| 2024 | ₹5B | 74.1% (59.1%) | Opr Margin | 17.46 | Debt/Equity | - | |||||
| 2025 | ₹4B | -25.2% (-28.2%) | PreTax Margin | 16.06 | BV/Share | 117 | |||||
| 5Y Average FCF | ₹3B | 15.0% (55.7%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.48% | Historical US Bond Yield: | 4.40% | ||||||||
| Discount Rate (WACC): | 7.00% | Current US Bond Yield: | 3.48% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (15.0%) | ||||||||||
| 2026 | ₹4B | MBG Intrinsic Value | ₹78 | ||||||||
| 2027 | ₹5B | ||||||||||
| 2028 | ₹5B | ||||||||||
| 2029 | ₹6B | ||||||||||
| 2030 | ₹6B | ||||||||||
| 2031 | ₹6B | ||||||||||
| Terminal Value | ₹141B | Net Worth/Share | ₹118 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹120B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹4B | ₹307 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹0 | WACC | 6.5% | 289 | 314 | 345 | 385 | 438 | |||
| Equity Value | ₹123B | 7.1% | 257 | 276 | 299 | 328 | 365 | ||||
| Shares Outstanding | 401,751,784 | 7.8% | 232 | 247 | 264 | 285 | 312 | ||||
| 8.4% | 211 | 223 | 236 | 253 | 272 | ||||||
| DCF Intrinsic Value | ₹307 | 9.0% | 194 | 203 | 214 | 227 | 242 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||